JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

146.15

-0.81%↓

Inicio・Lista de Acciones・Savara Inc

Savara Inc

Abierto

SectorSalud

4.41 3.28

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.27

Máximo

4.46

Métricas clave
By Trading Economics
Ingresos	-3.8M -30M
Margen de beneficio	-10,677.941
Empleados	59
EBITDA	-1.9M -30M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+111.19% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	244M 710M
Apertura anterior	1.13
Cierre anterior	4.41

Noticias sobre sentimiento de mercado

By Acuity

12%

88%

14 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

2.76 / 2.84 Soporte y Resistencia

Savara Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 oct 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

CSL Delays Flu-Vaccine Spinoff, Cuts Guidance As U.S. Vaccination Rates Decline

27 oct 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Australia's AUB Opens Books to EQT After Receiving $3.44 Billion Takeover Offer

27 oct 2025, 21:42 UTC

Ganancias

Waste Management 3Q Revenue Climbs, Sees Fiscal Year Revenue at Low End of Prior View

27 oct 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Easing U.S.-China Trade Tensions -- Market Talk

27 oct 2025, 23:42 UTC

Charlas de Mercado

Gold Rises on Likely Technical Recovery -- Market Talk

27 oct 2025, 23:37 UTC

Charlas de Mercado

Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

27 oct 2025, 23:00 UTC

Ganancias

The Good Vibes Are Back on Wall Street -- WSJ

27 oct 2025, 22:45 UTC

Adquisiciones, fusiones, absorciones

Australia's AUB Opens Books to EQT After Receiving $3.44B Takeover Offer

27 oct 2025, 22:06 UTC

Charlas de Mercado

Ganancias

Nucor Expects Weaker Steel Market in 4Q -- Market Talk

27 oct 2025, 22:05 UTC

Ganancias

China Southern Airlines: Continued Improvements in Business Environment Supported Results >1055.HK

27 oct 2025, 22:04 UTC

Ganancias

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct 2025, 22:04 UTC

Ganancias

China Southern Airlines 3Q Net CNY3.84B, Up 20.3% on Year >1055.HK

27 oct 2025, 22:03 UTC

Ganancias

China Southern Airlines 3Q Rev CNY51.37B, Up 3.0% on Year >1055.HK

27 oct 2025, 21:27 UTC

Ganancias

Waste Management 3Q Rev Climbs, Sees FY Rev at Low End of Prior View

27 oct 2025, 21:19 UTC

Ganancias

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct 2025, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

27 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: Decrease From Prior Rev Expectations Is Primarily Related to Further Decline in Recycled Commodity Pricing, Modestly Lower Rev Expectations From Healthcare Solutions >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: 2025 Free Cash Flow Guidance Remains Between $2.8B and $2.9B >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: 2025 Total Co Rev Is Now Expected Approximately $25.275B >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: Affirming 2025 Adjusted Operating EBITDA Guidance Between $7.475B and $7.625B >WM

27 oct 2025, 20:31 UTC

Ganancias

Nucor Sees 4Q Earnings Lower Than 3Q

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Steel Mills Total Shipments 6.43M Tons >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q EPS $2.63 >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Net $607M >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Sales $8.52B >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Adj EPS $1.98 >WM

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Rev $6.44B >WM

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Net $603M >WM

Comparación entre iguales

Cambio de precio

Savara Inc Esperado

Precio Objetivo

By TipRanks

111.19% repunte

Estimación a 12 meses

Media 9.25 USD 111.19%

Máximo 16 USD

Mínimo 2 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Savara Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Savara Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

2.76 / 2.84Soporte y Resistencia

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Sentimiento

By Acuity

14 / 373 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.